Veracyte Inc (VCYT)
NASDAQ:VCYT
Want to see VCYT full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.44Last Year’s EPS
0.44Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.Company Guidance
Strong Top-Line Growth
Total revenue of $139.1M, up 21% year-over-year; testing revenue $135.1M, up 26% year-over-year.
Volume Expansion
Total volume ~47,600 tests, up 17% YoY; testing volume ~45,200 tests, up 19% YoY; Decipher ~28,000 tests (24% YoY growth); Afirma ~17,200 tests (12% YoY growth).
Improved Pricing and ASP
Blended testing ASP $2,980, up 6% YoY (normalized ex-prior period collections $2,900, up 3% YoY); Decipher ASP growth outpaced Afirma.
Margin Expansion and Profitability
Non-GAAP gross margin 75.7%, up 350 basis points YoY; testing gross margin 70.4%, up 230 basis points YoY; GAAP net income $28.7M and adjusted EBITDA $42.8M (30.8% of revenue), up 73% YoY and above long-term 25% target.
Strong Cash Position and Cash Generation
Generated $35.2M of cash from operations in Q1 and ended the quarter with $439.1M in cash, cash equivalents, and short-term investments.
Operational Improvements for Afirma
Completed full transition to V2 transcriptome workflow, improving no-result rate and contributing ~400 basis points to volume growth in the quarter and enabling broader sample recovery.
Decipher Clinical and Commercial Momentum
Decipher sustained >20% quarterly growth since acquisition; ~30% growth across high-risk categories (radical prostatectomy, biochemical recurrence, metastatic); extensive evidence base with multiple Phase 3 trials (GUIDANCE >2,000 enrolled, PREDICT-RT, ENZIMET readout at ASCO).
Upcoming Product Catalysts
Prosigna LDT commercial launch on track by midyear with OPTIMA Phase 3 ASCO presentation in June; TruMRD whole-genome MRD platform expected to launch initially in MIBC by end of Q2.
Expanding Evidence and Research Assets
Decipher GRID and Afirma GRID research databases expanding; Decipher slide digitization nearing completion (>350,000 images) to support digital pathology/AI collaborations; multiple external validations and conference presentations (AACR, ASCO GU, AUA).
Balanced Investment While Maintaining Profitability
Management increased R&D and S&M investments to support launches and product development while delivering higher adjusted EBITDA and strong operating leverage.
VCYT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VCYT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $32.97 | $41.19 | +24.93% |
Feb 25, 2026 | $35.72 | $38.75 | +8.48% |
Nov 04, 2025 | $36.12 | $46.04 | +27.46% |
Aug 06, 2025 | $23.97 | $27.68 | +15.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Veracyte Inc (VCYT) report earnings?
Veracyte Inc (VCYT) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Veracyte Inc (VCYT) earnings time?
Veracyte Inc (VCYT) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VCYT EPS forecast?
VCYT EPS forecast for the fiscal quarter 2026 (Q2) is 0.44.